Approach to diabetes management in patients with CVD

Trends in Cardiovascular Medicine

Volumn 26, Issue 2, 2016, Pages 165-179

  Lathief, Sanam ^a   Inzucchi, Silvio E ^a,b  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Congestive heart failure (CHF); Coronary artery disease (CAD); CVD; Impaired fasting glucose (IFG); Impaired glucose tolerance (IGT); Major adverse CV events (MACE); Peripheral arterial disease (PAD); Sulfonylurea (SU); Thiazolidinedione (TZD); Type 2 diabetes (T2DM)

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES CONTROL; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CLASSIFICATION; COMPLICATION; DIABETES COMPLICATIONS; DISEASE MANAGEMENT; HYPERGLYCEMIA; OUTCOME ASSESSMENT;

CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DISEASE MANAGEMENT; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84959100907     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2015.05.005     Document Type: Review

References (96)

1. CDC. National Diabetes Statistics Report; 2014.
2. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 2002, 287:2570-2581.
3. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
4. Preis S.R., Hwang S.J., Coady S., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735.
5. Young L.H., Wackers F.J., Chyun D.A., et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. J Am Med Assoc 2009, 301:1547-1555.
6. Faglia E., Favales F., Calia P., et al. Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care 2002, 25:2032-2036.
7. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
8. Collins R. Heart protection study finds simvastatin reduces vascular risk in a wide range of high-risk patients. Am J Manag Care 2002, Suppl:6.
9. Malmberg K., Yusuf S., Gerstein H.C., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000, 102:1014-1019.
10. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
11. Ross S., Gerstein H.C., Eikelboom J., Anand S.S., Yusuf S., Pare G. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur Heart J 2015, 36:1454-1462.
12. Fox R. American Heart Association 2001 scientific sessions: late-breaking science-statins: the new aspirin?. Circulation 2001, 104:E9051-E9052.
13. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
14. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
15. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
16. Kannel W.B., Neaton J.D., Wentworth D., et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J 1986, 112:825-836.
17. Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614-620.
18. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
19. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
20. Diabetes Care 2014, 37(Suppl 1):S14-80. Standards of medical care in diabetes-2014.
21. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63:2889-2934.
22. American Diabetes Association. Standards of Medical Care in Diabetes-2015. The Journal of Clinical and Applied Research and Education 2015;38(Suppl I):ISSN 0149-5992.
23. Grant R.W., Donner T.W., Fradkin J.E., et al. Professional Practice Committee for the Standards of Medical Care in Diabetes-2015. Diabetes Care 2015, 38(Suppl 1):S88-S89.
24. Sowers J.R., Epstein M., Frohlich E.D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053-1059.
25. Gerstein H.C., Yusuf S., Mann J.F.E., et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 355:253-259.
26. Lindholm L.H., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
27. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br Med J 1998, 317:703-713.
28. Cushman W.C., Evans G.W., Byington R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585.
29. James P.A., Oparil S., Carter B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). J Am Med Assoc 2014, 311:507-520.
30. Curb J.D., Pressel S.L., Cutler J.A., et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. J Am Med Assoc 1996, 276:1886-1892.
31. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
32. Despres J.P., Lamarche B., Mauriege P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
33. Fontbonne A.M., Eschwege E.M. Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care 1991, 14:461-469.
34. Lemieux I., Lamarche B., Couillard C., et al. Total cholesterol/HDL cholesterol ratio vs. LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001, 161:2685-2692.
35. Pyorala M., Miettinen H., Laakso M., Pyorala K. Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 2000, 23:1097-1102.
36. Wolk R., Bertolet M., Brooks M.M., et al. Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial. Eur J Prev Cardiol 2014.
37. Nathan D.M., et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
38. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
39. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2. Diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
40. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
41. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
42. Zoungas S., Chalmers J., Neal B., et al. Follow-up of blood-pressure lowering and glucose control in Type 2 diabetes. N Engl J Med 2014, 371:1392-1406.
43. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
44. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
45. Group A.S., Gerstein H.C., Miller M.E., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011, 364:818-828.
46. Gerstein H.C., Miller M.E., Genuth S., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011, 364:818-828.
47. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326.
48. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
49. Goldfine A.B. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008, 359:1092-1095.
50. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
51. U.S. Food and Drug Administration FDA. Guidance for industry.
52. Knatterud L. University GroupDiabetes Program (UGDP). Encyclopedia of Biostatistics, Online© 2005 2005, John Wiley & Sons.
53. Goldner M.G., Knatterud G.L., Prout T.E. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. J Am Med Assoc 1971, 218:1400-1410.
54. Knatterud G.L., Klimt C.R., Levin M.E., Jacobson M.E., Goldner M.G. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. J Am Med Assoc 1978, 240:37-42.
55. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes 1975, 24(Suppl 1):65-184.
56. Lachin J.M., White N.H., Hainsworth D.P., Sun W., Cleary P.A., Nathan D.M. Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 2015, 64:631-642.
57. Lachin J.M., Genuth S., Cleary P.A., Davis M.D., Nathan D.M. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000, 342:381-389.
58. Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(Suppl 2):B21-B29.
59. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
60. Kooy A., de Jager J., Lehert P., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009, 169:616-625.
61. Roussel R., Travert F., Pasquet B., et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010, 170:1892-1899.
62. Riddle M.C. Counterpoint: intensive glucose control and mortality in ACCORD-still looking for clues. Diabetes Care 2010, 33:2722-2724.
63. Zoungas S., Patel A., Chalmers J., et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363:1410-1418.
64. Moritz T., Duckworth W., Abraira C. Veterans Affairs diabetes trial-corrections. N Engl J Med 2009, 361:1024-1025.
65. Currie C.J., Poole C.D., Jenkins-Jones S., Gale E.A., Johnson J.A., Morgan C.L. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012, 35:299-304.
66. Morgan C.L., Poole C.D., Evans M., Barnett A.H., Jenkins-Jones S., Currie C.J. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. Journal Clin Endocrinol Metab 2012, 97:4605-4612.
67. Roumie C.L., Hung A.M., Greevy R.A., et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012, 157:601-610.
68. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J Am Med Assoc 2002, 287:360-372.
69. Masoudi F.A., Inzucchi S.E. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 2007, 99:113b-132b.
70. Klepzig H., Kober G., Matter C., et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999, 20:439-446.
71. Goke B. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 2002, 1:329-336.
72. Erdmann E., Song E., Spanheimer R., van Troostenburg de Bruyn A.R., Perez A. Observational follow-up of the PROactive study: a 6-year update. Diabetes Obes Metab 2014, 16:63-74.
73. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
74. Turnbull F.M., Abraira C., Anderson R.J., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.
75. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Br Med J 1997, 314:1512-1515.
76. Cheung N.W., Wong V.W., McLean M. The hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006, 29:765-770.
77. Malmberg K., Ryden L., Wedel H., et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005, 26:650-661.
78. Gerstein H.C., Bosch J., Dagenais G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012, 367:319-328.
79. Ghatak S.B., Patel D.S., Shanker N., Srivstava A., Deshpande S.S., Panchal S.J. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. Curr Diabetes Rev 2010, 6:410-421.
80. Jose T., Inzucchi S.E. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res 2012, 9:109-116.
81. White W.B., Cannon C.P., Heller S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327-1335.
82. Scirica B.M., Braunwald E., Raz I., et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014, 130:1579-1588.
83. Zannad F., Cannon C.P., Cushman W.C., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015, 385:2067-2076.
84. Udell J.A., Cavender M.A., Bhatt D.L., Chatterjee S., Farkouh M.E., Scirica B.M. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. lancet Diabetes Endocrinol 2015, 3:356-366.
85. Inzucchi S.E., McGuire D.K. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 2008, 117:574-584.
86. Buse J.B., Klonoff D.C., Nielsen L.L., et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007, 29:139-153.
87. Petrie J.R. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 2013, 12:130.
88. Yamamoto H., Lee C.E., Marcus J.N., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002, 110:43-52.
89. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
90. Monami M., Cremasco F., Lamanna C., et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011:215764.
91. Inzucchi S.E., Zinman B., Wanner C., et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015, 12:90-100.
92. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
93. Holman R.R., Bethel M.A., Chan J.C., et al. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Am Heart J 2014, 168:e23-e29.
94. Holman R.R., Sourij H., Califf R.M. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014, 383:2008-2017.
95. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111:583-590.
96. Eurich D.T., Weir D.L., Majumdar S.R., et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013, 6:395-402.